Allopeptide-pulsed dendritic cells and composite tissue allograft survival

✍ Scribed by Vu T. Nguyen; Aurele Taieb; Justin M. Sacks; Jignesh V. Unadkat; Julio A. Clavijo; Haena Kim; Maryam Feili-Hariri; W. P. Andrew Lee

• Book ID: 102514726
• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 270 KB
• Volume: 27
• Category: Article
• ISSN: 0738-1085
• DOI: 10.1002/micr.20314

✦ Synopsis

Abstract

Composite tissue allografts (CTAs) contain their own reservoir of vascularized bone marrow, offering novel aspects for the induction of donor‐specific tolerance. Additionally, the manipulation of recipient dendritic cells, pulsed with donor allopeptide, has been shown to engender solid organ allograft survival. To exploit these modalities, we have developed a protocol utilizing injection of recipient bone marrow‐derived dendritic cells (BMDCs) pulsed with a donor‐derived peptide for use in CTA transplantation. Six days prior to orthotopic hind‐limb transplantation, Lewis rats received IV injection of donor allopeptide‐pulsed, recipient BMDCs, in conjunction with a single dose of anti‐lymphocyte serum. Control groups displayed signs of allograft rejection within 5 days postoperatively. Animals within the primary experimental cohort demonstrated prolongation of graft survival to an average of 8 days, and exhibited low numbers of donor T cells. The use of BMDCs in conjunction with transient immunosuppression has potential therapeutic application for induction of donor‐antigen‐specific tolerance to hind limb allografts. © 2007 Wiley‐Liss, Inc. Microsurgery, 2007.